Want to join the conversation?
$AGN said in 2Q16, topline sales of the branded business was $3.7Bil, up more than 9% compared to the prior year, excluding Namenda IR, divestitures and FX. Six of the company's most important brands grew double-digits globally, excluding FX. $AGN is building on its therapeutic areas and four of the seven areas grew by more than 15% in 2Q16.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?